ONCAlert | 2017 San Antonio Breast Cancer Symposium

Interim Analysis of a Study Exploring Indoximod/Pembrolizumab Combo in Melanoma

Yousef Zakharia, MD
Published Online:11:06 AM, Thu April 6, 2017

Yousef Zakharia, MD, assistant professor, University of Iowa, Holden Comprehensive Cancer Center, discusses an interim analysis of the phase II clinical trial investigating the IDO pathway inhibitor indoximod in combination with pembrolizumab (Keytruda) for patients with advanced melanoma. 
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.